Kezar Life Sciences Inc
(NAS:KZR)
$
6.51
-0.07 (-1.06%)
Market Cap: 47.50 Mil
Enterprise Value: -83.98 Mil
PE Ratio: 0
PB Ratio: 0.35
GF Score: 30/100 Kezar Life Sciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 02:50PM GMT
Release Date Price:
$12.2
(+1.67%)
Unidentified Participant
(audio in progress) Healthcare investment banking division here at Morgan Stanley.
Before we get started, I have to read a brief research disclosure. For important disclosures please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
We have the distinct pleasure of having John Fowler, CEO of Kezar Life Sciences. Thank you very much for making the trek out here.
John Fowler
Kezar Life Sciences, Inc. - CEO & Co-Founder
[Good to be here.]
Questions & Answers
Unidentified Participant;John Fowler
Kezar Life Sciences, Inc. - CEO &
Yeah. So John, maybe just to get us started, maybe you can tell us a little bit about your background. And also tell us how the Kezar story evolved over the years and how you got everything started.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot